751 related articles for article (PubMed ID: 24237632)
21. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
[TBL] [Abstract][Full Text] [Related]
22. Development of cannabidiol as a treatment for severe childhood epilepsies.
Williams CM; Stephens GJ
Br J Pharmacol; 2020 Dec; 177(24):5509-5517. PubMed ID: 32986848
[TBL] [Abstract][Full Text] [Related]
23. Cannabidiol-enriched oil in children and adults with treatment-resistant epilepsy-does tolerance exist?
Uliel-Sibony S; Hausman-Kedem M; Fattal-Valevski A; Kramer U
Brain Dev; 2021 Jan; 43(1):89-96. PubMed ID: 32713661
[TBL] [Abstract][Full Text] [Related]
24. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
[TBL] [Abstract][Full Text] [Related]
25. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
[TBL] [Abstract][Full Text] [Related]
26. Cannabis for Pediatric Epilepsy.
Huntsman RJ; Tang-Wai R; Shackelford AE
J Clin Neurophysiol; 2020 Jan; 37(1):2-8. PubMed ID: 31895184
[TBL] [Abstract][Full Text] [Related]
27. Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia.
Neubauer D; Perković Benedik M; Osredkar D
Epilepsy Behav; 2018 Apr; 81():79-85. PubMed ID: 29526578
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
[TBL] [Abstract][Full Text] [Related]
29. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
[TBL] [Abstract][Full Text] [Related]
30. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.
Tzadok M; Uliel-Siboni S; Linder I; Kramer U; Epstein O; Menascu S; Nissenkorn A; Yosef OB; Hyman E; Granot D; Dor M; Lerman-Sagie T; Ben-Zeev B
Seizure; 2016 Feb; 35():41-4. PubMed ID: 26800377
[TBL] [Abstract][Full Text] [Related]
31. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
Anderson LL; Heblinski M; Absalom NL; Hawkins NA; Bowen MT; Benson MJ; Zhang F; Bahceci D; Doohan PT; Chebib M; McGregor IS; Kearney JA; Arnold JC
Br J Pharmacol; 2021 Dec; 178(24):4826-4841. PubMed ID: 34384142
[TBL] [Abstract][Full Text] [Related]
32. Cannabis and epilepsy.
Thomas RH; Cunningham MO
Pract Neurol; 2018 Dec; 18(6):465-471. PubMed ID: 30337476
[TBL] [Abstract][Full Text] [Related]
33. Second-line cannabis therapy in patients with epilepsy.
Braun E; Gualano FM; Siddarth P; Segal E
Clin Neurol Neurosurg; 2023 Apr; 227():107638. PubMed ID: 36870086
[TBL] [Abstract][Full Text] [Related]
34. Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy.
Kochen S; Villanueva M; Bayarres L; Daza-Restrepo A; Gonzalez Martinez S; Oddo S
Epilepsy Behav; 2023 Jul; 144():109210. PubMed ID: 37196452
[TBL] [Abstract][Full Text] [Related]
35. Cannabidiol treatment of severe refractory epilepsy in children and young adults.
Zilmer M; Olofsson K
Dan Med J; 2021 Apr; 68(5):. PubMed ID: 33913416
[TBL] [Abstract][Full Text] [Related]
36. Cannabis for pediatric epilepsy: protocol for a living systematic review.
Elliott J; DeJean D; Clifford T; Coyle D; Potter B; Skidmore B; Alexander C; Repetski AE; McCoy B; Wells GA
Syst Rev; 2018 Jul; 7(1):95. PubMed ID: 30021618
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoids in treatment-resistant epilepsy: A review.
O'Connell BK; Gloss D; Devinsky O
Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
[TBL] [Abstract][Full Text] [Related]
38. Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy.
Caraballo R; Reyes G; Demirdjian G; Huaman M; Gutierrez R
Seizure; 2022 Feb; 95():56-63. PubMed ID: 34999381
[TBL] [Abstract][Full Text] [Related]
39. Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients.
Caraballo R; Valenzuela GR
Seizure; 2021 Nov; 92():238-243. PubMed ID: 34624613
[TBL] [Abstract][Full Text] [Related]
40. Cannabidiol and refractory epilepsy: parental and caregiver perspectives of participation in a compassionate access scheme.
Harte S; Singh Y; Malone S; Heussler H; Wallace G
BMC Health Serv Res; 2022 Feb; 22(1):173. PubMed ID: 35144615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
